Meeting
2016 ASCO Annual Meeting
Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
Authors
Wu Zhang
Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Wu Zhang , Mitsukuni Suenaga , Marta Schirripa , Shu Cao , Dongyun Yang , Martin D. Berger , Jordan David West , Yan Ning , Takeru Wakatsuki , Tetsuo Mashima , Satoshi Okazaki , Yuji Miyamoto , Diana L. Hanna , Federica Marmorino , Lisa Salvatore , Roberto Moretto , Beatrice Borelli , Afsaneh Barzi , Fotios Loupakis , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3580)
DOI
10.1200/JCO.2016.34.15_suppl.3580
Abstract #
3580
Poster Bd #
277
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
First Author: Mitsukuni Suenaga
Poster
2018 Gastrointestinal Cancers Symposium
Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer.
First Author: Mitsukuni Suenaga
Poster
2017 Gastrointestinal Cancers Symposium
Role of genetic polymorphisms in CCL5/CCR5 axis to predict efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
First Author: Mitsukuni Suenaga
Poster
2023 ASCO Annual Meeting
Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.
First Author: Arvind Dasari